Navigation Links
Potentia Pharmaceuticals' Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
Date:11/10/2008

AMD Patients Treated with POT-4 Demonstrate No Adverse Toxic Effects

ATLANTA, Nov. 10 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), presented Phase I data last week during the Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) Annual Meeting in Atlanta, GA. The data was from the ASaP (Assessment of Safety of Intravitreal POT-4 Therapy for Patients with Neovascular Age-Related Macular Degeneration) clinical trial for the company's leading drug candidate, POT-4, which is being developed for the treatment of AMD.

The ASaP trial is a first-in-man, multi-center, single escalating dose study. The interim results of this trial revealed no drug-related toxicity based on clinical signs, ophthalmic examinations, or laboratory results at any time point monitored in patients treated with up to 150 microgram/dose of POT- 4. Additionally, no serious adverse events and no identifiable intraocular inflammation were reported.

Preliminary results indicate that intravitreal POT-4 is safe, and the data accumulated so far support the continued investigation of POT-4 for the treatment of both dry and wet AMD with larger randomized clinical trials to further define its efficacy profile.

"These safety data strongly support the further development of POT-4 as a potential treatment for patients with AMD," said Cedric Francois, President and CEO of Potentia Pharmaceuticals. "We believe that the product has significant promise based on these early-stage findings and look forward to further testing of the compound in higher doses as we continue this trial."

About POT-4

POT-4 is a complement inhibitor, which shuts down the complement activation cascade that could otherwise lead to local inflammation, tissue damage and upregulation of angiogenic factors such as vascular endothelial growth factor (VEGF) in the eye.
'/>"/>

SOURCE Potentia Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
3. Gladstone scientists uncover potential mechanism of memory loss in Alzheimers disease
4. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
7. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
8. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
9. Discovery of creator gene for cerebral cortex points to potential stem cell treatments
10. Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs
11. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...FirstCall/--PDLBioPharma,Inc.(PDL)(Nasdaq: PDLI )t...09astheex-dividenddateforits$200millionspecialdivi...ansactioncompletedonNovember2,2009.Thedividendwill...therecorddate,December1,2009.NASDAQhassettheapprox...ommonstockforpurposesoftheex-dividenddateonNovembe...
(Date:11/23/2009)...Call/-YMBioSciencesInc.(NYSEAmex: YMI ;TSX:YM),ali...ndadvancesadiverseportfolioofpromisingcancer-relat...edthatCytopia(ASX:CYT)hascommencedenrollmentofaPha...teredJAK1/JAK2inhibitor.Thetrialisbeingconductedat...topiaintoYMhasbeenpreviouslyannouncedandispendinga...
(Date:11/23/2009)...all/--NeogenCorporation(Nasdaq: NEOG )announcedtod...oardofDirectorsatthecompany,srecentannualmeetingof...erienceinthefood,agriculture,andtradeindustriesand...conomicsatVirginiaTechUniversity.FromJanuary2006un...egotiatorwiththerankofambassador. ,, "Sinceourf...
(Date:11/23/2009)...cidin disinfectant solution and wipes are reliable...t H1N1 and Influenza A., , ...tec Inc, the leading manufacturer of clean room p...infectants have been deemed by the EPA as effecti...emic 2009 H1N1 influenza A virus (the swine flu). ...
Breaking Biology Technology:PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4Richard T. Crowder Joins Neogen's Board of Directors 2Sporicidin Brand Disinfectant Kills H1N1 in 3 Minutes 2
...-owned businesses to the $1 million annual revenue...s, perhaps none more important than information te...out of the recent Wisconsin Make Mine a Million ...ged to leverage information technology to a greate...rk. , ,The advice they absorbed from the likes of ...
...ch, a partner with the law firm Michael Best & Fr...Riske, the firm,s director of government affairs ....tment of Energy has announced $200 million in new...s funding opportunity is open to applicants with p...and development to design, construction, and opera...
...a Green Bay anti-spam solution provider, has intro...than 100,000 users and 20 million e-mails per day....appliance, was unveiled at this week,s Interop exh...to combat increasing threats from spam, phishing a...eIQ 3.0, the company,s newest anti-spam engine. , ...
Other Biology Technology:Learning from the big boys: With technology, women urged to go gradual 2Learning from the big boys: With technology, women urged to go gradual 3Wisconsin applicants urged to pursue DOE funding for cellulosic biomass 2
(Date:11/23/2009)...Ill. Two new studies reveal in unprecedented deta... to assemble new proteins and guide them toward th...sed molecular dynamics flexible fitting (MDFF) to ...rominent molecular partners. , The first study,...es , concerns the intimate signaling between the r...
(Date:11/23/2009)...like frogs and toads have existed for 360 million ...a new aquatic fungus is threatening to make many o...ember issue of Microbiology Today . , The fung...nd to be associated with waves of amphibian extinc...ia in the 1990,s. Bd infects over 350 amphibian sp...
(Date:11/23/2009)...roach to classify the gender of six-week-old turke...eing killed shortly after birth, according to Dr. ...nology in Germany and his team. Their use of infra...birds shows that it is a fast and accurate method ...stry to identify and select female eggs for breedi...
Breaking Biology News(10 mins):Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3Rescuing male turkey chicks 2Dr Oz Host of The Dr Oz Show to Accept Honorary CLIO Healthcare Award Live at Nielsens First Ever CLIO Healthcare Awards Mixer 59549 1Dr Oz Host of The Dr Oz Show to Accept Honorary CLIO Healthcare Award Live at Nielsens First Ever CLIO Healthcare Awards Mixer 59549 2Dr Oz Host of The Dr Oz Show to Accept Honorary CLIO Healthcare Award Live at Nielsens First Ever CLIO Healthcare Awards Mixer 59549 3The Effects of Health on Wealth 3A New Study Reveals Individuals Without Health Insurance at Risk for Financial Catastrophe 59546 1The Effects of Health on Wealth 3A New Study Reveals Individuals Without Health Insurance at Risk for Financial Catastrophe 59546 2The Effects of Health on Wealth 3A New Study Reveals Individuals Without Health Insurance at Risk for Financial Catastrophe 59546 3BioInformatics LLC New Report The Market Outlook for Research Products in FY2010 14491 1BioInformatics LLC New Report The Market Outlook for Research Products in FY2010 14491 2BioInformatics LLC New Report The Market Outlook for Research Products in FY2010 14491 3
...ncer Center at Thomas Jefferson University in Phil...n regulating aging also blocks prostate cancer cel...nter director Richard Pestell, M.D., Ph.D., hope t...standing the development of prostate cancer and le... member of a family of enzymes called sirtuins tha...
...role in mediating the outcome of competition betwe...-bearing conquistadors in the New World--or, on a ...eria to spread their viruses to competing bacteria...fferent general ways in which bacteria compete wit...egy seems to be particularly effective under diffe...
...als and the general public alike have been acutely...from a flu pandemic. Although many people might st...he infamous 1918-1920 pandemic--and the possibilit...ost trepidation. , Strangely, researchers still... particular strain of the flu virus in that pandem...
Other Biology News:Jefferson scientists find aging gene also protects against prostate cancer development 2Different strategies underlie the ecology of microbial invasions 2Recurrence of a flu pandemic similar to infamous 1918 flu could kill 62 million 2Recurrence of a flu pandemic similar to infamous 1918 flu could kill 62 million 3
CultureWell multiwell cell culture system CWI 50R-1.0 *plate and insert four 24 mm x 50 mm coverslips per insert fifty 1 mm-deep wells per coverslip* *set of 10* from Molecular Probes (Invitrogen)
...uct contains 5 ml of DETACHaBEAD Mouse CD4, polycl...cells from Dynabeads Mouse CD4 (L3T4). Detach pos... Mouse CD4 using DETACHaBEAD Mouse CD4. The isolat...on including flow cytometry, functional studies an...
CoverWell imaging chamber gasket with adhesive, one chamber, 20 mm diameter, 1.0 mm deep *set of 40* from Molecular Probes (Invitrogen)
Rattler Plating Beads from Zymo Research
Biology Products: